ଡୁଟାସ୍ଟେରାଇଡ

ଡୁଟାସ୍ଟେରାଇଡ
Clinical data
Trade names	Avodart, others; Combodart, Duodart (with tamsulosin)
Synonyms	GG-745; GI-198745; GI-198745X; N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
AHFS/Drugs.com	monograph
MedlinePlus	a603001
Pregnancy; category	US: X (Contraindicated) ; Not to be used during pregnancy;
Routes of; administration	By mouth
Drug class	5α-Reductase inhibitor
ATC code	G04CB02 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	60%
Protein binding	99%
Metabolism	Liver (CYP3A4)
Metabolites	• 4'-Hydroxydutasteride; • 6'-Hydroxydutasteride; • 1,2-Dihydrodutasteride; (All three active)
Elimination half-life	4–5 weeks
Excretion	Feces: 40% (metabolites); Urine: 5% (unchanged)
Identifiers
	IUPAC name (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide;
CAS Number	164656-23-9 ;
PubChem CID	6918296;
IUPHAR/BPS	7457;
DrugBank	DB01126 ;
ChemSpider	5293502 ;
UNII	O0J6XJN02I;
KEGG	D03820 ;
ChEBI	CHEBI:521033 ;
ChEMBL	CHEMBL1200969 ;
ECHA InfoCard	100.166.372
Chemical and physical data
Formula	C27H30F6N2O2
Molar mass	୫୨୮.୫୪ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c1cc(c(cc1)C(F)(F)F)NC(=O)[C@@H]3[C@]2(CC[C@H]4[C@H]([C@@H]2CC3)CC[C@H]5NC(=O)\C=C/[C@]45C)C;
	InChI InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1 ; Key:JWJOTENAMICLJG-QWBYCMEYSA-N ;
(verify)

ଡୁଟାସ୍ଟେରାଇଡ (ଇଂରାଜୀ ଭାଷାରେ Dutasteride, ଏକ ବିକ୍ରୟ ନାମ ଆଭୋଡାର୍ଟ/ Avodart) ଏକ ଔଷଧ ଯାହା ବର୍ଦ୍ଧିତ ପ୍ରୋସ୍ଟେଟ ରୋଗର ଲକ୍ଷଣମାନଙ୍କର ଚିକିତ୍ସା ନିମନ୍ତେ ଦିଆଯାଏ ।^[୪]^[୫] ଏହାର ଉପକାରୀତା ପ୍ରାୟ କିଛି ମାସ ପରେ ଜଣାଯାଏ ।^[୫] ଏହା ବ୍ୟତୀତ ପୁରୁଷଙ୍କର ମୁଣ୍ଡ ବାଳ ଝଡ଼ିବାର ଚିକିତ୍ସା ନିମନ୍ତେ ଓ ମହିଳାଙ୍କର ହରମୋନ ଥେରାପିରେ (hormone therapy) ବ୍ୟବ‌ହାର କରାଯାଏ ।^[୬]^[୭] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୪]^[୮]

ଡୁଟାସ୍ଟେରାଇଡର ସାଧାରଣ ପ୍ରତିକ୍ରିୟାରେ ଯୌନ ସମସ୍ୟା, ସ୍ତନ ଦରଜ ଓ ସ୍ତନ ବୃଦ୍ଧି ହୋଇପାରେ ।^[୪] ଏହା ବ୍ୟତୀତ କେତେକ ପ୍ରକାରର ପ୍ରୋସ୍ଟେଟ କର୍କଟ, ଅବସାଦ ଓ ଆଞ୍ଜିଓଇଡିମା ହୋଇପାରେ ।^[୪]^[୫] ଗର୍ଭାବସ୍ଥାରେ ଓ ଯୌନ ସାଥୀ ଏହାର ବ୍ୟବ‌ହାର କଲେ ଶିଶୁର କ୍ଷତି ହୁଏ ।^[୪]^[୫] ଡୁଟାସ୍ଟେରାଇଡ ଏକ ପ୍ରକାର ୫ -ରିଡକ୍ଟେଜ ଇନହିବିଟର (5α-reductase inhibitor) ଓ ଏକ ଆଣ୍ଟିଆଣ୍ଡ୍ରୋଜେନ (antiandrogen) ଔଷଧ ।^[୨] ଏହା ଏକ ଏଞ୍ଜାଇମ ଇନହିବିଟର (decreasing|) ଯାହା ଡାଇହାଇଡ୍ରୋଟେସ୍ଟୋସ୍ଟିରନ (dihydrotestosterone/ DHT) ନାମକ ଏକ ପ୍ରକାର ଯୌନ ହରମୋନ (sex hormone) ଆଣ୍ଡ୍ରୋଜେନର (androgen) ବାୟୋସିନ୍ଥେସିସ (production|) କମେଇ ଦେଇ କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୯]^[୪]

Dutasteride ସନ ୧୯୯୩ରେ ଗ୍ଲାକ୍ସୋସ୍ମିଥକ୍ଲାଇନଦ୍ୱାରା (GlaxoSmithKline) ପେଟେଣ୍ଟ ହେବା ପରେ ସନ ୨୦୦୧ରେ ଡାକ୍ତରୀ ବ୍ୟବ‌ହାର ନିମନ୍ତେ ସ୍ୱୀକୃତ ହୋଇଥିଲା ।^[୧୦]^[୪] ଏହା ଜେନେରିକ ଔଷଧ ନାମରେ (generic medication) ବିକ୍ରୟ ହୁଏ ।^[୫] ସନ ୨୦୧୯ରେ ସଂଯୁକ୍ତ ରାଷ୍ଟ୍ରରେ (United Kingdom) ଏନଏଚଏସକୁ (NHS) ଏହାର ଏକ ମାସର ଡୋଜ ପିଛା ପ୍ରାୟ ୧୨ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ କରିବାକୁ ପଡ଼ୁଥିଲା ।^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ର ଆମେରିକାରେ ଏହାର ଏକ ମାସ ଡୋଜର ହୋଲସେଲ ମୂଲ୍ୟ ୬.୬୬ ଆମେରିକୀୟ ଡଲାର ।^[୧୧] ସନ ୨୦୧୬ରେ ଏହାର ୧ ନିୟୁତରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ ହୋଇ ସର୍ବାଧିକ ପ୍ରେସକ୍ରିସନ ତାଲିକାର ୨୭୪ତମ ସ୍ଥାନରେ ଥଲା । ^[୧୨]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ ^୧.୮ Thomas L. Lemke; David A. Williams (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1286–1287. ISBN 978-0-7817-6879-5.
↑ ^୨.୦ ^୨.୧ Ulrike Blume-Peytavi; David A. Whiting; Ralph M. Trüeb (26 June 2008). Hair Growth and Disorders. Springer Science & Business Media. pp. 182, 369. ISBN 978-3-540-46911-7.
↑ Jacqueline Burchum; Laura Rosenthal (2 December 2014). Lehne's Pharmacology for Nursing Care. Elsevier Health Sciences. pp. 803–. ISBN 978-0-323-34026-7.
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ "Dutasteride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 18 March 2019.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 769. ISBN 9780857113382.
↑ Jerry Shapiro; Nina Otberg (17 April 2015). Hair Loss and Restoration, Second Edition. CRC Press. pp. 39–. ISBN 978-1-4822-3199-1.
↑ Wesp LM, Deutsch MB (2017). "Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons". Psychiatr. Clin. North Am. 40 (1): 99–111. doi:10.1016/j.psc.2016.10.006. PMID 28159148.
↑ Wu C, Kapoor A (2013). "Dutasteride for the treatment of benign prostatic hyperplasia". Expert Opin Pharmacother. 14 (10): 1399–408. doi:10.1517/14656566.2013.797965. PMID 23750593.
↑ Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M (February 2010). "An overview on 5alpha-reductase inhibitors". Steroids. 75 (2): 109–53. doi:10.1016/j.steroids.2009.10.005. PMID 19879888.
↑ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 483. ISBN 9783527607495.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

ବାହ୍ୟ ଲିଙ୍କ

Drug information from the NIH
Frye, S. (2006). "Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor". Current Topics in Medicinal Chemistry. 6 (5): 405–21. doi:10.2174/156802606776743101. PMID 16719800.

[LemkeWilliams2008-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ ^୧.୭ ^୧.୮ Thomas L. Lemke; David A. Williams (2008). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 1286–1287. ISBN 978-0-7817-6879-5.

[Blu2008-2] ୨.୦ ^୨.୧ Ulrike Blume-Peytavi; David A. Whiting; Ralph M. Trüeb (26 June 2008). Hair Growth and Disorders. Springer Science & Business Media. pp. 182, 369. ISBN 978-3-540-46911-7.

[BurchumRosenthal2014-3] Jacqueline Burchum; Laura Rosenthal (2 December 2014). Lehne's Pharmacology for Nursing Care. Elsevier Health Sciences. pp. 803–. ISBN 978-0-323-34026-7.

[AHFS2019-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ ^୪.୬ "Dutasteride Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Retrieved 18 March 2019.

[BNF76-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ ^୫.୪ ^୫.୫ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 769. ISBN 9780857113382.

[ShapiroOtberg2015-6] Jerry Shapiro; Nina Otberg (17 April 2015). Hair Loss and Restoration, Second Edition. CRC Press. pp. 39–. ISBN 978-1-4822-3199-1.

[Trans2017-7] Wesp LM, Deutsch MB (2017). "Hormonal and Surgical Treatment Options for Transgender Women and Transfeminine Spectrum Persons". Psychiatr. Clin. North Am. 40 (1): 99–111. doi:10.1016/j.psc.2016.10.006. PMID 28159148.

[Wu2013-8] Wu C, Kapoor A (2013). "Dutasteride for the treatment of benign prostatic hyperplasia". Expert Opin Pharmacother. 14 (10): 1399–408. doi:10.1517/14656566.2013.797965. PMID 23750593.

[Agg2010-9] Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M (February 2010). "An overview on 5alpha-reductase inhibitors". Steroids. 75 (2): 109–53. doi:10.1016/j.steroids.2009.10.005. PMID 19879888.

[Fis2006-10] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery (in ଇଂରାଜୀ). John Wiley & Sons. p. 483. ISBN 9783527607495.

[NADAC2019-11] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[12] "The Top 300 of 2019". clincalc.com. Retrieved 22 December 2018.

[୪]

[୫]

[୬]

[୭]

[୮]

[୧]

[୨]

[୩]

[୯]

[୧୦]

[୧୧]

[୧୨]